Scienture Holdings, Inc. — requested filing identification
Entity mismatch: The supplied filing is TRXADE GROUP, INC.’s Form 10-Q, not a filing under the name Scienture Holdings, Inc. The summary below reflects the supplied filing. It covers the unaudited quarter and nine months ended September 30, 2018.
Business context
Trxade operates a web-based business-to-business pharmaceutical marketplace connecting independent pharmacies with pharmaceutical wholesalers. The company reported more than 8,500 registered pharmacy members. Integra Pharma Solutions had limited operations; Alliance Pharma Solutions had no operations or revenue. Community Specialty Pharmacy (CSP), acquired in October 2018, was not included in the quarter’s financial statements.
Financial performance
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | $847,471 | $735,869 | $2,538,082 | $2,141,540 |
| Gross profit | $845,126 | $735,869 | $2,535,737 | $2,141,540 |
| Operating income | $91,829 | $89,615 | $222,003 | $234,848 |
| Net income | $94,249 | $76,193 | $197,031 | $149,077 |
- Revenue rose 15.2% in Q3 and 18.5% for the nine-month period, which management attributed to increased platform transaction-fee income and customer growth through marketing and training.
- Gross margin was approximately 99.7% in Q3 and 99.9% for the nine months. Operating margin was approximately 10.8% and 8.7%, respectively; net margin was approximately 11.1% and 7.8%.
- Net income increased 23.7% for Q3 and 32.2% for the nine months. Nine-month operating income nevertheless declined 5.5%, as operating expenses rose faster than revenue.
- Nine-month general and administrative expense, excluding stock-based compensation, was $2,180,686, up from $1,684,640. Stock-option expense was $133,048, compared with $222,052 in 2017. Q3 total operating expenses were $753,297, including $44,976 of option expense.
- Other income was $22,500 in Q3 and $22,500 for the nine months; the filing does not clearly explain its nature in the supplied text. Interest expense declined to $40,028 for nine months from $136,715. Debt-extinguishment losses were $7,444 versus $16,556.
Cash flow, liquidity and debt
- At September 30, 2018, cash was $592,765, total current assets $1,220,997, current liabilities $682,855, and working capital $538,142. The current ratio was approximately 1.79, compared with approximately 1.16 at December 31, 2017.
- For the nine months, operating cash flow was $231,315, financing cash flow was $177,536, and cash increased $408,851. Financing included $300,000 from common-stock issuance, partly offset by debt repayments. No investing cash flow was reported.
- Recorded debt was approximately $544,052: $321,500 current convertible debt and $222,552 of long-term related-party notes. The $181,500 convertible note is due May 2019; related-party convertible notes of $140,000 were classified as current. The company paid off a $10,739 third-party promissory note during the period.
- Stockholders’ equity improved from a deficit of $311,933 at year-end 2017 to positive equity of $325,590. The company issued 300,000 shares for $300,000 in July; associated warrants covered 161,538 shares at a $0.01 exercise price.
Outlook, risks and notable items
- Management estimated approximately $2.425 million of operating expenses and working-capital needs for the next 12 months and said additional funding would be needed to expand the platform and customer base. It planned to seek financing but cautioned that funding may not be available on favorable terms or at all, and that equity financing would dilute shareholders. Management believed liquidity could support operations for the foreseeable future, but gave no assurance of significant positive operating cash flow.
- On October 15, 2018, the company acquired CSP for $300,000 cash, a $300,000 promissory note bearing 10% annual interest and due in 36 months, and a warrant for 405,507 shares at $0.01. The acquisition’s purchase-price allocation and pro forma financial information were not yet available; the resulting cash use, added debt and potential dilution are not reflected in the September 30 balance sheet.
- The company stated that disclosure controls and procedures were not effective at period-end. It reported no material change in internal control over financial reporting during the nine months, no legal proceedings, and no change in risk factors from its 2017 Form 10-K.
- There was no specific earnings or revenue guidance. The filing warns that forward-looking statements are subject to risks and actual results may differ materially.
Key facts for investors to verify
- Confirm the issuer identity: the supplied 10-Q is for TRXADE GROUP, INC., despite the request naming Scienture Holdings, Inc.
- Review the October CSP acquisition’s final accounting, financing impact, operating contribution and warrant dilution.
- Assess the company’s ability to fund the stated $2.425 million 12-month requirements, given its cash balance and reliance on additional financing.
- Examine the reasons for ineffective disclosure controls and any remediation since the filing.
- Verify the terms, maturities and related-party nature of outstanding debt, and the potential dilution from warrants, options and convertible notes.